NDAORALCAPSULE
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
6/8 — Strong
JALYN (dutasteride and tamsulosin hydrochloride) by Viatris (2) is 5-alpha reductase inhibitors [moa]. Approved for symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate, symptomatic bph in men with an enlarged prostate. First approved in 2010.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JALYN is a fixed-dose combination of dutasteride (5-alpha reductase inhibitor) and tamsulosin (alpha-1A adrenergic antagonist) administered orally as a capsule. It treats symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate by reducing prostate size and improving urinary flow through dual mechanism of action.
$0.001BPart D
LOE ApproachingDeclining
As LOE approaches, JALYN brand teams are transitioning from growth to defensive strategies, with smaller team sizes focused on patient retention and managed care negotiations.
Mechanism of Action
5-alpha Reductase Inhibitors
Pharmacologic Class:
5-alpha Reductase Inhibitor
Worked on JALYN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.